Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Duvelisib

🥰Excellent
Catalog No. T1988Cas No. 1201438-56-3
Alias IPI-145, INK1197

Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ, with effects on p110δ (IC50 value is 0.0025 μM), p110γ (IC50 value is 0.274 μM), p110β (IC50 value is 0.85 μM) and p110α (IC50 value is 1.602 μM).

Duvelisib

Duvelisib

🥰Excellent
Purity: 99.45%
Catalog No. T1988Alias IPI-145, INK1197Cas No. 1201438-56-3
Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ, with effects on p110δ (IC50 value is 0.0025 μM), p110γ (IC50 value is 0.274 μM), p110β (IC50 value is 0.85 μM) and p110α (IC50 value is 1.602 μM).
Pack SizePriceAvailabilityQuantity
2 mg$40In Stock
5 mg$61In Stock
10 mg$85In Stock
50 mg$158In Stock
100 mg$256In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Duvelisib"

Select Batch
Purity:99.45%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Duvelisib (INK1197, IPI-145) is a selective inhibitor of phosphatidylinositol 3-kinase (PI3K) and p100δ, with effects on p110δ (IC50 value is 0.0025 μM), p110γ (IC50 value is 0.274 μM), p110β (IC50 value is 0.85 μM) and p110α (IC50 value is 1.602 μM).
Targets&IC50
PI3Kδ:23 pM(Ki), PI3Kγ:243 pM(Ki), PI3Kβ:1564 pM(Ki)
In vitro
METHODS: Primary AML blasts (AML#2 and AML#5) were treated with Duvelisib (INK1197, IPI-145) (0.1, 0.5, 1 μM) and cultured for 4 hours. They were then incubated with BMSC conditioned medium for 5 minutes. Whole cell extracts were prepared and Western blot analysis was performed for pAKT (s473 and t308) and total AKT, as well as pMAPK and total MAPK.
RESULTS Duvelisib (INK1197, IPI-145) inhibited BMSC CM-induced pAKT (s473 and t308) activation at 0.1 μM; Duvelisib (INK1197, IPI-145) blocked blast migration through its inhibitory effect on AKT phosphorylation at the t308 site. [1]
In vivo
METHODS: We used an Eμ-TCL1 adoptive transfer mouse model of CLL. After Duvelisib (INK1197, IPI-145) (100 mg/kg, once daily, oral, for 21 days),
RESULTS Duvelisib (INK1197, IPI-145) significantly reduced the CLL burden (CD19 CD5 B cells) in the peripheral blood of mice; at the same time, the total number of CD3 T cells in the mice was also lower, but the CD4/CD8 ratio was also reduced. [2]
AliasIPI-145, INK1197
Chemical Properties
Molecular Weight416.86
FormulaC22H17ClN6O
Cas No.1201438-56-3
SmilesC[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1
Relative Density.1.474 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: < 1 mg/ml

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Duvelisib | purchase Duvelisib | Duvelisib cost | order Duvelisib | Duvelisib chemical structure | Duvelisib in vivo | Duvelisib in vitro | Duvelisib formula | Duvelisib molecular weight